Pykus Therapeutics

Pykus Therapeutics is a health care startup that was founded in 2016 with the aim of revolutionizing retinal surgery. The company's innovative solution revolves around creating a dissolvable intraocular surgical device to improve outcomes and reduce the pain associated with retinal surgery. Co-founded by ophthalmology residents at the Massachusetts Eye and Ear Infirmary and Harvard Medical School, Pykus Therapeutics has developed an innovative hydrogel to replace intraocular gas used during retinal surgery. This breakthrough is set to alleviate significant patient burdens, including the need for face-down positioning, long periods of impaired vision, and restrictions on air travel for weeks. Their most recent accomplishment includes a $2.49M Venture Round investment on 04 February 2021, with key investment from Partners Innovation Fund and ShangPharma. With its pioneering approach and potential to transform the field of ophthalmology, Pykus Therapeutics presents an exciting opportunity for investors looking to contribute to the advancement of medical technology and patient care.